ArticleScientific reports2022
Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Comparison of the gut microbiota in older people with and without sarcopenia: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Associations between gut microbiota and sarcopenia or its defining parameters in older adults: A systematic review.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Association of Gut Microbiome with Muscle Mass, Muscle Strength, and Muscle Performance in Older Adults: A Systematic Review.International journal of environmental research and public health · 2024Pooled it
- Changes in the gut microbiota of patients with sarcopenia based on 16S rRNA gene sequencing: a systematic review and meta-analysis.Frontiers in nutrition · 2024Pooled it
- Gut microbiome and frailty: insight from genetic correlation and mendelian randomization.Gut microbes · 2023Pooled it
- The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.Hepatology communications · 2024Trial
- mTOR-Gut Microbiome Interaction in Aging: Fusobacterium nucleatum, Resistance Training and Multi-nutrient Supplementation Effects in Aged Male Rats.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Rumen Metagenomic and Muscle Metabolomic Characterization of Meat Quality in Duolang Sheep at Different Ages.Foods (Basel, Switzerland) · 2026Article
- Associations Between the Gut Microbiota and Physical Activity, Sedentary Behaviour and Physical Function in Community-Dwelling Older Adults.Journal of aging research · 2026Article
- Emodin treatment is associated with enhanced resistance toFrontiers in immunology · 2026Article
- A review of omics studies in sarcopenia: from molecular mechanisms to hepatic-gut-muscle interactions in chronic liver disease comorbidity.Frontiers in cellular and infection microbiology · 2025Review
- Gut matters in microgravity: potential link of gut microbiota and its metabolites to cardiovascular and musculoskeletal well-being.Nutrition & metabolism · 2024Review
- KL-Biome (Postbiotic Formulation ofInternational journal of molecular sciences · 2024Article
- Exploring the Gut Microbiota-Muscle Axis in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2024Review
- Review
- Chronic Training Induces Metabolic and Proteomic Response in Male and Female Basketball Players: Salivary Modifications during In-Season Training Programs.Healthcare (Basel, Switzerland) · 2023Article
- The gut microbiota from maintenance hemodialysis patients with sarcopenia influences muscle function in mice.Frontiers in cellular and infection microbiology · 2023Article
- Sarcopenia in Chronic Liver Disease: A Metabolic Perspective.Journal of clinical and translational hepatology · 2022Review
- Hepatogenous diabetes: Knowledge, evidence, and skepticism.World journal of hepatology · 2022Review
- Gut-muscle crosstalk. A perspective on influence of microbes on muscle function.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is thought to be related to the microbiome, but not enough reports in chronic liver disease (CLD) patients. In addition to the differences in microbiome, the role of the microbiome in the gut is also important to be clarified because it has recently been shown that the microbiome may produce branched-chain amino acids (BCAAs) in the body. In this single-center study, sixty-nine CLD patients were divided by skeletal muscle mass index (SMI) into low (L-SMI: n = 25) and normal (N-SMI: n = 44). Microbiome was analyzed from stool samples based on V3-4 region of bacterial 16S rRNA). L-SMI had a lower Firmicutes/Bacteroidetes ratio than N-SMI. At the genus level, Coprobacillus, Catenibacterium and Clostridium were also lower while the Bacteroides was higher. Predictive functional profiling of the L-SMI group showed that genes related to nitrogen metabolism were enriched, but those related to amino acid metabolism, including BCAA biosynthesis, were lower. The genes related to 'LPS biosynthesis' was also higher. The microbiome of CLD patients with low muscle mass is characterized not only by high relative abundance of gram-negative bacteria with LPS, but also by the possibility of low potential for amino acid synthesis including BCAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.